BAYER AG NA O.N.
Commented by Nico Popp on January 26th, 2022 | 11:01 CET
Bayer, MAS Gold, BASF: 5.7% dividend? These intrinsic values score now!
According to capital market strategist Ulrich Stephan from Deutsche Bank, substantial stocks could have an advantage in the upcoming market phase. The reason: When interest rates rise, the refinancing costs for growth companies increase significantly, as they usually do not write any or few profits. Reason enough to take a closer look at two of the best-known German substance companies and ask whether there are also growth stocks with substance.
Read
Commented by Nico Popp on January 13th, 2022 | 11:03 CET
Bayer, First Hydrogen, NEL: This is how innovative investing works!
Innovation pays off - especially on the stock market. That is because innovative products generate price fantasy, which can generate rich returns on the stock market within a very short period of time. In addition to classic trend themes, such as hydrogen, established companies can also score with innovations. We present three stocks and explain whether they offer opportunities or not.
Read
Commented by Armin Schulz on January 12th, 2022 | 13:42 CET
Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.
Read
Commented by Stefan Feulner on January 11th, 2022 | 11:20 CET
Steinhoff, Aspermont, Bayer - Crazy speed
In terms of digitization, Germany lags light years behind other countries. Most of the big Internet success stories were written in the USA with Facebook, Google, Amazon and Apple. Yet new developments are coming faster and faster, and the digital transformation continues unabated. Down Under, the next success story is currently being built: The transformation of a venerable publishing house into a digital media company. The next big step is on the horizon, which should bring great potential for investors with the help of new shareholders. But the story is still in its infancy.
Read
Commented by Stefan Feulner on January 5th, 2022 | 11:10 CET
Avoiding penalties with Bayer, MAS Gold and BASF
According to the "Allianz Global Wealth Report", global financial assets have grown strongly. Private households alone had gross financial assets of over EUR 200 trillion worldwide in the past year, representing an increase of almost 10% compared to the previous year. The reason for the high savings rate was mainly the uncertainty surrounding the Corona pandemic. Now, with punitive interest rates and rising inflation, there are renewed threats to citizens' assets. One way out would be to invest in precious metals and build up long-term equity positions, primarily in the value sector.
Read
Commented by Armin Schulz on January 3rd, 2022 | 08:59 CET
Bayer, Memiontec, Deutsche Telekom - With blue chips through inflation
When inflation rates started to rise in the USA and Germany, all sides initially said this phenomenon was temporary. In the meantime, it has become clear that the experts were wrong. Inflation has come to stay and brings inflation rates we have not seen for decades. In November, it was 5.2% in Germany. Typically, it would be the ECB's job to control inflation, but its hands are tied because of the interest rate problem. That leaves investors with the question of how best to protect their money. One option is to look at blue chips, three of which we will examine in more detail today.
Read
Commented by André Will-Laudien on December 30th, 2021 | 11:53 CET
Royal Dutch, Saturn Oil + Gas, Bayer: The oil price and the pandemic in 2022
COVID-19 is a black swan for the economy, but does the pandemic favor lower or higher oil prices? Not an easy determination because, for one thing, the measures to contain the pandemic significantly lower economic activity. Production delays and supply chain failures occur, so oil demand should fall there. On the other hand, a shortage of inputs and constraints in logistics lead to higher delivery and waiting times, thus creating some hoarding pressure, which increases demand for the black gold. Due to the shortness of history, the actual connection is also little researched, i.e. how it really is could remain hidden from us for some time. Who benefits from the current cycle of price increases?
Read
Commented by Carsten Mainitz on December 28th, 2021 | 11:26 CET
Novavax, XPhyto Therapeutics, Bayer - Corona shares for 2022!
The head of the Robert Koch Institute, Lothar Wieler, warned a few days ago that the healthcare system would be overburdened and critical care structures impaired if the feared Omicron wave could not be curbed. This situation illustrates that the pandemic is far from letting us go. Vaccine manufacturers and pharmaceutical companies will continue to benefit. Their shares should also be on the winning side next year.
Read
Commented by Stefan Feulner on December 23rd, 2021 | 11:15 CET
Novavax, Sativa Wellness Group, Bayer - The next wave ignites
There is great concern in society due to the Omicron variant. Reason enough for politicians to further tighten measures, even for the approximately 70% of fully vaccinated people in the Federal Republic. The federal and state governments decided on stricter contact restrictions, large events without spectators and a new vaccination target. By the end of January, a further 30 million booster, first and second vaccinations are to be achieved. As a result, vaccine manufacturers are experiencing another boom. Meanwhile, a new vaccine is coming to Germany to change the minds of vaccination skeptics.
Read
Commented by Stefan Feulner on December 21st, 2021 | 13:03 CET
BioNTech, Memiontec, Bayer - Catastrophic conditions
There is no question that the Corona pandemic must be fought by all means. Nevertheless, apart from the virus and the question of vaccination, testing and boosters, there are far worse problems on our planet. For example, did you know that in the top daily news, it is reported that some 2.2 billion people have no sustainable, safe and readily available access to drinking water? Or that 361,000 children under the age of five die each year from diarrheal diseases caused by dirty water and contaminated food? The issue of water will be increasingly prominent in the headlines over the next few years. You can already invest in tomorrow's winners.
Read